General Biologicals Corporation (4117)
TWSE TWSE Primary Summary
General Biologicals Corporation (4117) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has General Biologicals Corporation ever had a stock split?
General Biologicals Corporation Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. T.C. Lin CEO | TWSE Exchange | TW0004117007 ISIN |
| Taiwan Country | - Employees | - Last Dividend | 8 Sep 2025 Last Split | - IPO Date |
Overview
General Biologicals Corporation (GBC) is a pioneering entity dedicated to the advancement of in-vitro diagnostics on a global scale, with its roots firmly planted in Taiwan. Embarking on its journey in 1973, GBC has established a firm reputation for its remarkable contributions to healthcare through the research, development, production, and commercialization of diagnostic solutions. Its operations, sprawling beyond the Taiwanese borders, cater to an international clientele, emphasizing the company's commitment to addressing the global demands of healthcare diagnostics. With its headquarters in Hsinchu City, Taiwan, GBC stands as a testament to innovation and quality in the life sciences domain.
Products and Services
- ELISA and Chemiluminescence Immunoassay
- Molecular and Cell Diagnostic Services
- Point of Care Testing Services
- COVID-19 Solutions
- Digital Pathology
- Contract Development Manufacturing Organization (CDMO) Solutions
- Blood Screening Services
- Biomaterial
- Oral Care Products
These are foundational techniques employed by GBC for detecting and quantifying substances such as proteins, hormones, and antibodies in biological samples. They are pivotal in disease diagnosis and biological research, offering high specificity and sensitivity.
GBC's offerings in this category encompass a wide range of services aimed at understanding genetic and cellular characteristics critical for disease diagnosis, treatment, and research. By leveraging cutting-edge molecular techniques, the company aids in the identification of disease markers and genetic profiles.
With an emphasis on convenience and speed, GBC's point of care testing services facilitate immediate diagnostic results in clinical settings. This service model enhances patient care by enabling rapid decision-making and treatment initiation.
In response to the global pandemic, GBC rapidly developed and offered diagnostic solutions for COVID-19, including tests for the detection of the virus and antibodies. These solutions are crucial for managing and controlling the spread of the virus.
GBC integrates digital pathology solutions to transform traditional pathology into a digital format, enhancing diagnostic accuracy and efficiency. This innovative approach allows for advanced image analysis, storage, and sharing capabilities.
The company extends its expertise to provide comprehensive services for the development and manufacturing of diagnostic products. This includes assistance through all stages, from concept to commercialization, adhering to stringent quality standards.
Specializing in the detection of infectious diseases such as hepatitis and HIV, GBC offers blood screening services to ensure the safety of blood and blood products, a critical aspect of public health and transfusion medicine.
Under this segment, GBC supplies a range of antibody biomaterials and human plasma products. These biomaterials are essential for various research, diagnostic, and therapeutic applications.
Apart from its diagnostic and research-focused products, GBC also markets a line of oral care products under the brand name oh care. These products are designed to promote oral health and hygiene.
